GPER1 and ovarian carcinoma: This study of GPER in primary ovarian tumors and ovarian cancer cell lines was partly initiated because SERM molecules, like tamoxifen, have come in use as adjuvant therapy in patients with ovarian cancer, and these compounds are GPER agonists.